Showing posts with label Methadone. Show all posts
Showing posts with label Methadone. Show all posts

Monday, 9 May 2016

PubMed Update April 2016

23 for this month! Lots of interesting stuff, from large-scale epidemiology to randomized controlled trials.

Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, Aker J, Beck M, Harris J.
J Clin Pharmacol. 2016 May 5. doi: 10.1002/jcph.759. [Epub ahead of print]
Comment: Details on the pharmacokinetics and usability studies for the new nasal device.

Madah-Amiri D, Clausen T.
Addiction. 2016 May 3. doi: 10.1111/add.13400. [Epub ahead of print] No abstract available.
Comment: Large-scale naloxone requires public health support.

Wilkerson RG, Kim HK, Windsor TA, Mareiniss DP.
Emerg Med Clin North Am. 2016 May;34(2):e1-e23. doi: 10.1016/j.emc.2015.11.002. Epub 2016 Feb 17. Review.
Comment: Focuses on risk factors for problematic opioid use and naloxone.


Kunøe N, Opheim A, Solli KK, Gaulen Z, Sharma-Haase K, Latif ZE, Tanum L.
BMC Pharmacol Toxicol. 2016 Apr 28;17(1):18. doi: 10.1186/s40360-016-0061-1.
Comment: Methods paper for above planned study.

Arelin V, Schmidt JJ, Kayser N, Kühn-Velten WN, Suhling H, Eden G, Kielstein JT.
Clin Nephrol. 2016 Apr 27. [Epub ahead of print]
Comment: Doesn’t really remove methadone, so not useful in an overdose but also not problematic for patients on methadone undergoing light-chain removal.

Madah-Amiri D, Clausen T, Lobmaier P.
Drug Alcohol Depend. 2016 Apr 14. pii: S0376-8716(16)30034-5. doi: 10.1016/j.drugalcdep.2016.04.007. [Epub ahead of print]
Comment: Title is self-explanatory.

Weiner SG, Raja AS, Bittner JC, Curtis KM, Weimersheimer P, Hasegawa K, Espinola JA, Camargo CA Jr.
Acad Emerg Med. 2016 Apr 21. doi: 10.1111/acem.12992. [Epub ahead of print]
Comment: Intriguing look at ED policies in New England. 18% had an opioid screening tool, 78% used the PDMP, 41% alerted the primary doctor when prescribing opioids, 70% gave substance use treatment referrals, and 12% offered take-home naloxone.

Pade P, Fehling P, Collins S, Martin L.
Subst Abus. 2016 Apr 19:0. [Epub ahead of print]
Comment: Naloxone in a residential treatment program. Hopefully the first bit of data with much more to come.

Takeda MY, Katzman JG, Dole E, Bennett MH, Alchbli A, Duhigg D, Yonas H.
Subst Abus. 2016 Apr 19:0. [Epub ahead of print]
Comment: New Mexico study of 164 chronic pain patients on opioids who were provided naloxone. There were no overdoses.

Friedman MS, Manini AF.
J Med Toxicol. 2016 Apr 15. [Epub ahead of print]
Comment: Fascinating abstract – I don’t have full access. They set up “naloxone criteria” of (1) respiratory rate <12, miotic pupils, or drug paraphernalia, and (2) altered mental status by AVPU or GCS and then looked to see if those criteria predicted a beneficial effect of naloxone. They did – with an OR of 7 and 83% sensitivity. Miotic pupils were the best predictor of a response to naloxone. Authors also found that naloxone was underutilized – in only 44.2% of cases where it may have been beneficial. This is a fascinating area, as we don’t yet understand the reasons why naloxone is or is not administered in emergency services.

Darke S, Duflou J.
Addiction. 2016 Apr 15. doi: 10.1111/add.13429. [Epub ahead of print]
Comment: 6-MAM, the best way to confirm heroin as a cause of overdose death, is only present if the death occurs in under 30 minutes. In this study, 6-MAM was present in 43% of heroin overdose cases, suggesting that most people took longer to expire.

Lewis DA, Park JN, Vail L, Sine M, Welsh C, Sherman SG.
Am J Public Health. 2016 Apr 14:e1-e4. [Epub ahead of print]
Comment: Distribution program increased self-efficacy.

Chronister KJ, Lintzeris N, Jackson A, Ivan M, Dietze P, Lenton S, Kearley J, van Beek I.
Drug Alcohol Rev. 2016 Apr 13. doi: 10.1111/dar.12400. [Epub ahead of print]
Comment: First data on an Australian naloxone program. 83 people given naloxone. Among the 42% completing follow-up, 30 overdoses were successfully reversed and participants still felt informed and able to use naloxone.

Hoback J.
State Legis. 2016 Apr;42(4):9-13. No abstract available.
Comment: On a quick glance, seems a bit inflammatory.

Harned M, Sloan P.
Expert Opin Drug Saf. 2016 Apr 26:1-8. [Epub ahead of print]
Comment: Prospective trials are needed to evaluate longterm opioid therapy for chronic pain.

Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP.
N Engl J Med. 2016 Mar 31;374(13):1232-42. doi: 10.1056/NEJMoa1505409.
Comment: Pretty good data on extended-release naltrexone and low overdose risk. Unfortunately, overdose wasn’t specifically asked about, but instead was treated as any other adverse events in a clinical trial and had to be reported by the participants.

Yablonsky TA, Thompson GL.
W V Med J. 2016 Mar-Apr;112(2):16-7. No abstract available.
Comment: Can’t access, but there are a lot.

Hein H, Püschel K, Schaper A, Iwersen-Bergmann S.
Arch Kriminol. 2016 Jan-Feb;237(1-2):38-46. German.
Comment: Lockboxes.

Asplund J.
Hosp Health Netw. 2016 Jan;90(1):20, 22, 2.
Comment: This is apparently about police and naloxone.

Rudd RA, Aleshire N, Zibbell JE, Gladden RM.
MMWR Morb Mortal Wkly Rep. 2016 Jan 1;64(50-51):1378-82. doi: 10.15585/mmwr.mm6450a3.
Comment: Really well done. Discusses opioids in a sophisticated and honest manner. Impressive work from the CDC.

Larochelle MR, Liebschutz JM, Zhang F, Ross-Degnan D, Wharam JF.
Ann Intern Med. 2016 Jan 5;164(1):1-9. doi: 10.7326/M15-0038. Epub 2015 Dec 29.
Comment: Patients who have an overdose usually continue to receive opioids. If opioids stop, they have a lower risk of recurrent overdose.

Sgarlato A, deRoux SJ.
Forensic Sci Med Pathol. 2015 Sep;11(3):388-94. doi: 10.1007/s12024-015-9699-z. Epub 2015 Aug 2.
Comment: 36.7% of decedents had a valid opioid prescription; benzos were involved in 68.4% of cases with alprazolam the most common (35.1%).

Darke S, Slade T, Ross J, Marel C, Mills KL, Tessson M.
Addict Behav. 2015 Nov;50:78-83. doi: 10.1016/j.addbeh.2015.06.030. Epub 2015 Jun 14.
Comment: Heavy drinking was associated with overdose (OR 1.6).

Tuesday, 22 March 2016

PubMed Update February 2016

Ten articles for February 2016.

[No authors listed]
ED Manag. 2016 Feb;28(2):13-9.
Comments: Review of the new CDC opioid prescribing guidelines.

Lenton SR, Dietze PM, Jauncey M.
Med J Aust. 2016 Mar 7;204(4):146-7. No abstract available.
Comments: Naloxone can now be over the counter in Australia, but there’s some work to be done in product design.

King R.
NASN Sch Nurse. 2016 Mar;31(2):96-101. doi: 10.1177/1942602X16628890.
Comments: Naloxone for school nurses in Delaware.

Agahi M, Shakoori V, Marashi SM.
Sultan Qaboos Univ Med J. 2016 Feb;16(1):e113-4. doi: 10.18295/squmj.2016.16.01.022. Epub 2016 Feb 2. No abstract available.
Comments: Long QT interval is a side effect of high methadone doses.


Ahlner J, Holmgren A, Jones AW.
Forensic Sci Int. 2016 Feb 3;265:138-143. doi: 10.1016/j.forsciint.2016.01.036. [Epub ahead of print]
Comments: Yet another population that may benefit from overdose prevention programming – persons arrested for impaired driving.

Jones CM, Lurie PG, Compton WM.
Am J Public Health. 2016 Apr;106(4):689-90. doi: 10.2105/AJPH.2016.303062. Epub 2016 Feb 18.
Comments: Some increase in sales; much of this increase may be accounted for by a selected number of programs. These data were also presented at the FDA meeting on naloxone in July 2015.


Butler MM, Ancona RM, Beauchamp GA, Yamin CK, Winstanley EL, Hart KW, Ruffner AH, Ryan SW, Ryan RJ, Lindsell CJ, Lyons MS.
Ann Emerg Med. 2016 Feb 10. pii: S0196-0644(15)01567-X. doi: 10.1016/j.annemergmed.2015.11.033. [Epub ahead of print]
Comments: 59% of opioid dependent participants were initially exposed via a medical prescription to them and 29% of those prescriptions came from emergency departments.

McLean K.
Int J Drug Policy. 2016 Mar;29:19-26. doi: 10.1016/j.drugpo.2016.01.009. Epub 2016 Jan 18.
Comments: This is fascinating. Poverty and social isolation.

Paulozzi LJ, Zhou C, Jones CM, Xu L, Florence CS.
Pharmacoepidemiol Drug Saf. 2016 Feb 10. doi: 10.1002/pds.3980. [Epub ahead of print]
Comments: Studying opioid prescribing is really complicated, because it involves making sense of – and trying to quantify – very complex and confusing medical decisions. This is an interesting analysis attempting to determine how much documentation of concerning opioid use behaviors results in changes in opioid prescribing.

Haug NA, Bielenberg J, Linder SH, Lembke A.
Subst Abus. 2016 Jan-Mar;37(1):35-41. doi: 10.1080/08897077.2015.1129390.

Comments: Naloxone-trained individuals on Twitter “had the highest optimism and the lowest amount of burnout and stigma.” 

Monday, 9 November 2015

PubMed Update October 2015

28 in a month.

Eizadi-Mood N, Yaraghi A, Sharifian Z, Feizi A, Hedaiaty M, Sabzghabaee AM.
Mater Sociomed. 2015 Aug;27(4):276-9. doi: 10.5455/msm.2015.27.276-279.
Comments: Some interesting data on methadone toxicity in Iran. Length of stay was 33 hours (median). 90.3% survived. There were several complications. GCS on admission predicted survival. Useful data for economic modeling …

Zucker H, Annucci AJ, Stancliff S, Catania H.
Harm Reduct J. 2015 Nov 5;12(1):51. doi: 10.1186/s12954-015-0084-8.
PMID: 26541987 Free Article
Comments: Early report describing the establishment of a prison naloxone program in NY. Some of the most important work happening in this area…

Winstanley EL, Clark A, Wilder CM.
J Addict Med. 2015 Dec;9(6):503-4. doi: 10.1097/ADM.0000000000000160. No abstract available.
Comments: Can’t access. Meh.

Orkin AM, Bingham K, Buick JE, Klaiman M, Leece P, Kouyoumdjian F.
J Addict Med. 2015 Dec;9(6):502-3. doi: 10.1097/ADM.0000000000000161. No abstract available.
Comments: Also can’t access.

Clark A, Winstanley EL, Martsolf DS, Rosen M.
Addict Behav. 2015 Oct 8;53:141-145. doi: 10.1016/j.addbeh.2015.10.006. [Epub ahead of print] No abstract available.
Comments: Authors report on development of an electronic book on overdose prevention for use in addiction treatment settings.

Ashrafioun L, Gamble S, Herrmann M, Baciewicz G.
Subst Abus. 2015 Oct 29:0. [Epub ahead of print]
Comments: Those trained in intranasal naloxone were more confident than those trained in injectable. That is odd, as studies suggest that injectable is easier than intranasal.

Lev R, Petro S, Lee A, Lee O, Lucas J, Castillo EM, Egnatios J, Vilke GM.
Forensic Sci Int. 2015 Oct 22;257:347-352. doi: 10.1016/j.forsciint.2015.09.021. [Epub ahead of print]
Comments: The lack of data from methadone maintenance programs makes it quite challenging to interpret some of the methadone-related mortality data.

McAuley A, Aucott L, Matheson C.
Int J Drug Policy. 2015 Oct 1. pii: S0955-3959(15)00306-0. doi: 10.1016/j.drugpo.2015.09.011. [Epub ahead of print]
Comments: 9% of kits were likely to be used for overdose rescue. That looks like a rather low number, but it’s over a 3-month period. I suspect the annual rate is closer to 20% +/- 5%.

Davis CS, Carr D.
Drug Alcohol Depend. 2015 Oct 22. pii: S0376-8716(15)01695-6. doi: 10.1016/j.drugalcdep.2015.10.013. [Epub ahead of print]
Comments: Great paper, title says it all.

Jolley CJ, Bell J, Rafferty GF, Moxham J, Strang J.
PLoS One. 2015 Oct 23;10(10):e0140995. doi: 10.1371/journal.pone.0140995. eCollection 2015.
Comments: I like this study. The physiology of “overdose” is totally fascinating and nowhere near as simple as it seems.

Baillif-Couniou V, Kintz P, Sastre C, Pok PP, Chèze M, Pépin G, Leonetti G, Pelissier-Alicot AL.
J Forensic Leg Med. 2015 Sep 4;36:172-176. doi: 10.1016/j.jflm.2015.08.014. [Epub ahead of print]
Comments: Morphine overdose in an adolescent in France. It’s news there because they don’t see people dying of prescription opioids like in the U.S.

Wiebelhaus JM, Walentiny DM, Beardsley PM.
J Pharmacol Exp Ther. 2015 Oct 21. pii: jpet.115.228940. [Epub ahead of print]
Comments: Oxycodone works like other opioids.

Tucker D, Hayashi K, Milloy MJ, Nolan S, Dong H, Kerr T, Wood E.
Addict Behav. 2015 Oct 9;52:103-107. doi: 10.1016/j.addbeh.2015.10.002. [Epub ahead of print]
Comments: Benzo use is associated with lots of risk factors for negative health outcomes, including blood-borne virus transmission, among drug users.

Dailey M.
Addiction. 2015 Nov;110(11):1775-6. doi: 10.1111/add.13093. No abstract available.
Comments: Nice commentary, pointing out the opportunities for intervention among those who contact the medical system with an overdose.

Sivilotti ML.
Br J Clin Pharmacol. 2015 Aug 7. doi: 10.1111/bcp.12731. [Epub ahead of print] Review.
Comments: Fascinating differences between benzo and opioid-induced respiratory depression. Benzos cause apnea usually because the upper airway is blocked or collapses – so respiratory support is the need – and the antidote can lead to seizures. Opioids are different and naloxone much safer.

Cheatle MD, Webster LR.
Pain Med. 2015 Oct;16 Suppl 1:S22-6. doi: 10.1111/pme.12910. Review.
Comments: Opioids might be dangerous with sleep disorders.

Morris MD, Bates A, Andrew E, Hahn J, Page K, Maher L.
Drug Alcohol Depend. 2015 Nov 1;156:275-81. doi: 10.1016/j.drugalcdep.2015.09.025. Epub 2015 Sep 30.
Comments: Injection partnerships can have divergent benefits and risks.

Berlin J.
Tex Med. 2015 Oct 1;111(10):41-7.
Comments: Naloxone in Texas!

Lake S, Hayashi K, Buxton J, Milloy MJ, Dong H, Wood E, Montaner J, Kerr T.
Drug Alcohol Depend. 2015 Nov 1;156:297-303. doi: 10.1016/j.drugalcdep.2015.09.026. Epub 2015 Sep 30.
Comments: Interesting analysis – injecting prescription opioids didn’t by itself increase overdose risk. Injecting of both prescription opioids and heroin did, however. So there is probably some protection offered by the known doses and constituents in prescription opioids.

Martins SS, Sampson L, Cerdá M, Galea S.
Am J Public Health. 2015 Nov;105(11):e29-49. doi: 10.2105/AJPH.2015.302843.
Comments: Nice summary of global data looking at some basic overdose results. Mean/median rate of witnessed overdose in a drug user’s lifetime = 73/70%. Lifetime prevalence of experienced overdose was mean of 45.4% and median of 47%. Population-based overdose mortality rates varied from 0.4-46.6 / 100,000 person years (note, this is populationbased).

Humphreys K.
Health Aff (Millwood). 2015 Oct 1;34(10):1624-7. doi: 10.1377/hlthaff.2015.0934.
Comments: Review of naloxone based on summer 2015 FDA meeting.

Zalewska-Kaszubska J.
Vaccine. 2015 Oct 2. pii: S0264-410X(15)01369-9. doi: 10.1016/j.vaccine.2015.09.079. [Epub ahead of print] Review.
Comments: Really interesting idea – use antibodies against drugs, like cocaine, to manage overdose on those drugs. Excellent.

Partownavid P, Sharma S, Li J, Umar S, Rahman S, Eghbali M.
Anesth Analg. 2015 Aug;121(2):340-7. doi: 10.1213/ANE.0000000000000788.
Comments: Opioid receptors are required for rescuing people from the cardiac toxicity of bupivacaine overdose.

Rech MA, Donahey E, Cappiello Dziedzic JM, Oh L, Greenhalgh E.
Pharmacotherapy. 2015 Feb;35(2):189-97. doi: 10.1002/phar.1522. Epub 2014 Dec 4. Review.
Comments: Desomorphine. Blech.

Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM.
Drug Alcohol Depend. 2014 Dec 1;145:34-47. doi: 10.1016/j.drugalcdep.2014.10.001. Epub 2014 Oct 14. Review.
Comments: Not much.

Chakrapani V, Kamei R, Kipgen H, Kh JK.
Int J Prison Health. 2013;9(2):82-91. doi: 10.1108/17449201311326952.
Comments: Access is … no there.

Tacelosky DM, Alexander DN, Morse M, Hajnal A, Berg A, Levenson R, Grigson PS.
Behav Neurosci. 2015 Oct 26. [Epub ahead of print]
Comments: Holding drug exposure constant, reducing dopamine D2 receptors or that other thing (Wntless) results in more opioid craving.

Allread V, Paul S.
MD Advis. 2014 Fall;7(4):12-20. Review.
Comments: Can’t access. Review for New Jersey and rest of US regarding prescription opioids and heroin use.

Friday, 9 October 2015

PubMed Update September 2015

Twelve this month. Enjoy!

Ries R, Krupski A, West II, Maynard C, Bumgardner K, Donovan D, Dunn C, Roy-Byrne P.
J Addict Med. 2015 Oct;9(5):417-26. doi: 10.1097/ADM.0000000000000151.
Comment: Can’t access the full article, but the abstract suggests a fascinating look into opioid-using safety net primary care patients.

Kazour F, Soufia M, Rohayem J, Richa S.
Community Ment Health J. 2015 Sep 30. [Epub ahead of print]
Comment: Most studies of heroin users find that heroin is *not* the usual method of suicide attempts. Interestingly, this study finds something quite different, with nearly half of attempts being through heroin use in Lebanon.

Roxburgh A, Hall WD, Burns L, Pilgrim J, Saar E, Nielsen S, Degenhardt L.
Med J Aust. 2015 Oct 5;203(7):299.
Comment: Interesting paper exploring deaths related to one, low-potency, opioid. Those deaths seemed to be increasing, over a third were intentional (that’s much higher than other opioids), and a remarkably high proportion were polydrug – which makes sense since it would be tough to die from codeine alone.

Kampman K, Jarvis M.
J Addict Med. 2015 Oct;9(5):358-67. doi: 10.1097/ADM.0000000000000166.
Comment: Another that I can’t access but whose abstract looks compelling.

Kharasch ED, Regina KJ, Blood J, Friedel C.
Anesthesiology. 2015 Sep 19. [Epub ahead of print]
Comment: Ah, the complexities of methadone. Genetic differences in hepatic metabolism are more prominent in oral than intravenous methadone.


Kimber J, Larney S, Hickman M, Randall D, Degenhardt L.
Lancet Psychiatry. 2015 Sep 15. pii: S2215-0366(15)00366-1. doi: 10.1016/S2215-0366(15)00366-1. [Epub ahead of print]
Comment: There is likely a mortality benefit to buprenorphine in the initiation of treatment, but after that methadone and buprenorphine are comparable. I’ll admit that I’m a bit surprised by that – I would have expected an ongoing relative benefit to buprenorphine (there was a possible benefit to buprenorphine in all-cause mortality during the treatment time). Of note for treatment programs, even if the eventual treatment is methadone, it may be possible to avert the initiation mortality risk by starting with buprenorphine because the subsequent switch to methadone doesn’t come with the mortality risk.

Sumner SA, Mercado-Crespo MC, Spelke MB, Paulozzi L, Sugerman DE, Hillis SD, Stanley C.
Prehosp Emerg Care. 2015 Sep 18:1-6. [Epub ahead of print]
Comment: Really interesting analysis of medical examiner records. They looked at opioid overdose decedents who had undergone resuscitation efforts and then looked to see if they had received naloxone during those paramedic efforts. Naloxone was given in two-thirds of cases and was much more likely to be given to younger men with evidence of illicit drug use. Should paramedics be more willing to use naloxone in settings that don’t look like a “classic heroin overdose”? Or would that have negative effects? This is a really interesting topic for emergency medicine.

Winston I, McDonald R, Tas B, Strang J.
BMJ Case Rep. 2015 Sep 14;2015. pii: bcr2015210391. doi: 10.1136/bcr-2015-210391.
Comment: I can’t access this but the abstract purports that it is the “first-ever account” of a lay person titrating naloxone to respiratory function. Not to be snooty, but that’s really old news.

Fischer B, Murphy Y, Rudzinski K, MacPherson D.
Int J Drug Policy. 2015 Aug 14. pii: S0955-3959(15)00242-X. doi: 10.1016/j.drugpo.2015.08.007. [Epub ahead of print]
Comment: Canada’s conflicted drug policy.

Michel L, Lions C, Maradan G, Mora M, Marcellin F, Morel A, Spire B, Roux P, Carrieri PM; Methaville Study Group.
Compr Psychiatry. 2015 Oct;62:123-31. doi: 10.1016/j.comppsych.2015.07.004. Epub 2015 Jul 14.
Comment: Methadone patients with HCV are at *way* higher risk for suicide. Increasingly, studies suggest that there are real mental health costs to HCV and corresponding benefits to HCV treatment.

Fulton-Kehoe D, Sullivan MD, Turner JA, Garg RK, Bauer AM, Wickizer TM, Franklin GM.
Med Care. 2015 Aug;53(8):679-85. doi: 10.1097/MLR.0000000000000384.
Comment: The increasing risk of overdose with opioid dose is likely about linear and just knowing dose or dosing frequency/duration doesn’t tell you the whole picture. Unfortunately big data just doesn’t answer the deep questions about substance use.

Ahmad SA, Scolnik D, Snehal V, Glatstein M.
Am J Ther. 2015 Jan-Feb;22(1):e14-6. doi: 10.1097/MJT.0b013e318293b0e8. Review.
Comment: I can’t access the full article, but am not surprised that naloxone doesn’t reverse clonidine toxicity.